Summary & Overview
HCPCS A2037: G4derm plus/suprello, per milliliter
HCPCS Level II code A2037 designates G4derm plus/suprello, billed per milliliter, reflecting a dermatologic product used in outpatient dermatology and ambulatory procedure settings. Nationally, product-supply codes such as A2037 matter because they affect coverage determinations, site-of-service billing, and unit-based reimbursement for clinicians and facilities that supply and apply specialty dermatologic formulations.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns and benchmarks where available, a concise explanation of clinical context for product use in dermatology, and notes on common billing considerations tied to unit-based HCPCS supplies. The publication summarizes typical service settings and highlights operational implications for billing per milliliter.
The report covers benchmark pricing and reimbursement ranges when available, payer-specific coverage nuances, and coding best-practice considerations relevant to product-supply billing. Data not provided in the input are noted as unavailable rather than inferred. The content is presented for a national audience and does not address state-specific policy variations.
Billing Code Overview
HCPCS Level II code A2037 represents G4derm plus/suprello, billed per milliliter. This code denotes a dermatologic product supplied in liquid formulation, intended for topical or procedural dermatology use. The service type is a dermatologic product dispensing or supply, and the typical site of service is outpatient dermatology clinics, physician offices, or ambulatory procedure settings where topical or injectable dermatologic products are administered or applied.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an outpatient dermatology or wound care clinic administering a compounded topical or injectable dermatologic biologic product billed as A2037 (G4derm plus/suprello, per milliliter). The patient is an adult with a localized chronic wound, recalcitrant ulcer, or a focal dermatologic condition (for example, nonhealing venous stasis ulcer or an area of focal tissue loss) where a clinician applies or injects a biologic skin substitute or wound-healing adjunct directly into the wound bed or periwound tissue. The clinical workflow: the patient is evaluated by a dermatologist or wound-care specialist; indication and informed consent are documented; the wound is debrided or prepared; the appropriate volume of the product is drawn and delivered per manufacturer instructions into the wound bed or surrounding tissue; post-procedure wound dressing is applied; follow-up visits are scheduled to monitor healing and document response. Typical sites of service are outpatient dermatology clinics, wound-care centers, ambulatory surgical centers, and sometimes hospital outpatient departments. Common patient comorbidities include diabetes mellitus, peripheral vascular disease, or prior radiation to the area contributing to impaired healing. Relevant payors for authorization and billing include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |